newsfilter
← Latest News
GlobeNewswire·

Evelo Biosciences Provides Clinical and Business Updates

– Data from first three cohorts of EDP1815 Phase 2 trial in atopic dermatitis did not meet primary endpoint; unusually high placebo response rate observed –– Clear path to registration trials for EDP1815 in psoriasis